Pertussis Prevention Starts Here
Each visit is a new opportunity to help protect your patients against pertussis with Adacel.1
Adacel is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.
Routine Immunization Begins with Your Adacel Recommendation
Help eligible patients stay up to date with their pertussis protection.1
The first dose of Adacel is administered at least 5 years after the last dose of DTaPa or Tdb.1
Adacel is approved for a repeat vaccination as soon as 8 years after the initial Tdapc dose.1
Adacel for tetanus-prone wound management may be administered as early as 5 years after a previous dose of tetanus toxoid-containing vaccine.1
After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.
Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.
CONFIDENTLY HELP PRIORITIZE PERTUSSIS PREVENTION TODAY
- More than 180 million doses of Adacel have been distributed since licensure in 20052
- Adacel is approved for use in persons 10 through 64 years of age1
- Adacel is available in prefilled syringes and vials made without natural rubber latex1